Please ensure Javascript is enabled for purposes of website accessibility

5 of Last Week's Biggest Winners

By Rick Munarriz – Jan 12, 2014 at 7:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These five stocks posted double-digit percentage gains this past week.

What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.

Company

Jan. 10

Weekly Gain

Intrexon (PGEN -7.81%)

$29.87

27%

TASER International (AXON -2.12%)

$18.68

19%

BlackBerry (BB -0.83%)

$8.76

15%

LightInTheBox (LITB -0.77%)

$9.13

12%

MannKind (MNKD -2.22%)

$5.92

10%

Source: Barron's.

Let's start with Intrexon. The provider of synthetic biology solutions moved higher after announcing that its CEO will present at the J.P. Morgan Healthcare Conference. The presentation will be on Wednesday afternoon, giving the company the opportunity to educate the market on its UltraVector platform that facilitates the design and development of complex biological systems.

TASER moved higher after announcing a flurry of contracts to close out 2013. The stun-gun maker issued a press release detailing more than a dozen weapon deployments and more than two dozen organizations deploying TASER SMART weaponry.

BlackBerry closed higher every single trading day last week. The week kicked off with another executive hire, bringing in someone to run its devices division. BlackBerry then generated some buzz during the CES exposition by talking up smartphones with physical keyboards, like when the company was in its prime.

LightInTheBox moved higher after acquiring a social e-commerce company. LightInTheBox's all-cash deal for Seattle-based Ador gives it a physical stateside presence for the first time. LightInTheBox is based in China, where it sources formalwear and housewares that it sells overseas. Europe currently represents its biggest market. It remains to be seen whether Ador can move the needle for a company that has posted disappointing financials since going public last year, but investors seem to be excited about the push to shake things up by going shopping.

MannKind was on a roller-coaster ride, soaring on Thursday and tumbling on Friday. The Endocrinologic and Metabolic Drugs Advisory Committee is tentatively looking at April for a review of Afrezza, MannKind's potentially game-changing inhalable insulin treatment. If this past week's volatility was wild, one can only imagine the wild swings that wait in April based on the results of the review.

Longtime Fool contributor Rick Munarriz owns shares of LightInTheBox Holding and MannKind. The Motley Fool has no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Axon Enterprise Stock Quote
Axon Enterprise
AXON
$183.94 (-2.12%) $-3.98
MannKind Corporation Stock Quote
MannKind Corporation
MNKD
$4.41 (-2.22%) $0.10
BlackBerry Stock Quote
BlackBerry
BB
$4.80 (-0.83%) $0.04
LightInThe Box Holding Stock Quote
LightInThe Box Holding
LITB
$1.29 (-0.77%) $0.01
Precigen, Inc. Stock Quote
Precigen, Inc.
PGEN
$1.77 (-7.81%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.